PML bodies provide an important platform for the maintenance of telomeric chromatin integrity in embryonic stem cells

Fiona T. M. Chang1, James D. McGhie1, F. Lyn Chan1, Michelle C. Tang2, Melissa A. Anderson2, Jeffrey R. Mann2, K. H. Andy Choo2 and Lee H. Wong1,*

1Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia and
2Department of Paediatrics, University of Melbourne, Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, Flemington Road, Victoria 3052, Australia

Received November 6, 2012; Revised January 31, 2013; Accepted February 2, 2013

ABSTRACT

We have previously shown that α-thalassemia mental retardation X-linked (ATRX) and histone H3.3 are key regulators of telomeric chromatin in mouse embryonic stem cells. The function of ATRX and H3.3 in the maintenance of telomere chromatin integrity is further demonstrated by recent studies that show the strong association of ATRX/H3.3 mutations with alternative lengthening of telomeres in telomerase-negative human cancer cells. Here, we demonstrate that ATRX and H3.3 co-localize with the telomeric DNA and associated proteins within the promyelocytic leukemia (PML) bodies in mouse ES cells. The assembly of these telomere-associated PML bodies is most prominent at S phase. RNA interference (RNAi)-mediated knockdown of PML expression induces the disassembly of these nuclear bodies and a telomere dysfunction phenotype in mouse ES cells. Loss of function of PML bodies in mouse ES cells also disrupts binding of ATRX/H3.3 and proper establishment of histone methylation pattern at the telomere. Our study demonstrates that PML bodies act as epigenetic regulators by serving as platforms for the assembly of the telomeric chromatin to ensure a faithful inheritance of epigenetic information at the telomere.

INTRODUCTION

Telomeres are specialized structures that protect the chromosome ends. Telomere maintenance is essential for the unlimited proliferative potential of human cells. Many human tumor cells have acquired an indefinite replicative capacity by maintaining their telomeres through increased telomerase expression and activity. However, in 10–20% of tumors, a recombination-mediated Alternative Lengthening of Telomeres (ALT) mechanism is used (1–5). Hallmarks of ALT cancer cells include the highly heterogeneous length of their telomeres, ranging from very short to longer than 100 kb (3,6) and the presence of extra-chromosomal telomeric DNA (7,8).

Mammalian telomeres contain DNA and histone modifications characteristic of repressive chromatin. Knockout studies in mice have demonstrated the importance of DNA hypermethylation, H3K9me3 (H3 Lys9 trimethylation) and H4K20me3 (H4 Lys20 trimethylation) for negative regulation of telomere length and repression of telomeric recombination (9–11). However, unlike the somatic cell counterparts, pluripotent mouse embryonic stem (ES) cells comprise much lower H3K9me3 and H4K20me3 levels at telomeres (12,13). On induction of differentiation, these repressive chromatin marks are rapidly increased at telomeres, suggesting that the telomeric chromatin state, in this case, histone modification pattern in ES cells, is less ‘heterochromatic’ in nature and undergoes a dynamic configuration change during differentiation (12,13). It is interesting that a low density of H3K9me3 and H4K20me3 is also found at telomeres in induced pluripotent stem cells, highlighting the importance of the maintenance of a unique telomeric chromatin state in pluripotent cell types (14). This change in telomeric chromatin state during cellular differentiation also occurs in vivo in mice as demonstrated by the transition of transcriptionally active subtelomeric regions in ES cells to repressive chromatin in somatic tissues (15).

The telomere in mouse ES cells is enriched with ATRX (α-thalassemia mental retardation X-linked) and histone variant H3.3 (12,13). ATRX is a member of SWI2/SNF2
family of helicase/ATPases (16,17) that plays a role in controlling DNA methylation at ribosomal repeats, subtelomeres and chromosome Y satellite repeats (18). H3.3 is a H3 variant commonly, but not exclusively, associated with active chromatin (19,20). In mouse ES cells, the depletion of either ATRX or H3.3 induces a telomeric dysfunction phenotype (12,13), providing evidence for their function in maintaining telomeric chromatin integrity. Recent studies have shown that ATRX and its interacting partner Death domain associated protein (DAXX) (Death associated domain 6) act as chaperones that deposit H3.3 at the pericentric and telomeric DNA (21–23). The loss of ATRX/DAXX function results in an increase in pericentric satellite and telomeric transcription, providing evidence for the function of ATRX/DAXX/H3.3 as chromatin regulators at the repressive heterochromatin. Importantly, recent studies have also reported a common mutation in ATRX/DAXX/H3.3 in human ALT-positive cancers including the pancreatic neuroendocrine tumors, pediatric glioblastoma multiforme, neuroblastoma and several other cancers of the central nervous system (24–32), further implicating the role of ATRX/DAXX/H3.3 in the maintenance of telomere chromatin integrity.

Promyelocytic leukemia (PML) nuclear bodies are spheres of 0.1–1.0 μm in diameter found in the nucleus. They regulate cellular processes including gene transcription, tumor suppression, DNA replication and repair (33–35). Consistent with their multi-faceted role in cellular function, PML bodies contain a variety of regulatory proteins including PML, SP100, p53, pRb, HP-1, ATRX, DAXX and SUMO-1. In human ALT cancer cells, a distinct kind of PML bodies known as the ALT-associated PML bodies (APBs) is found. In these structures, telomeric DNA, telomere binding proteins (e.g. TERF-1, TERF-2) and DNA repair proteins (e.g. RAD50, Mre11, NBS1) co-localize with the PML protein (8,36). Although it is unclear as to whether APBs directly drive ALT activity, there is evidence that they promote ALT activity. The disassembly of APBs, as a result of RNAi-mediated knockdown of either PML or Mre11/Rad50/Nbs1 (MRN) proteins, leads to inhibition of telomere elongation in ALT cells (37–40).

Here, we show that ATRX, DAXX and H3.3 co-localize with telomeres at the PML bodies in pluripotent mouse ES cells. Other proteins found within these bodies include and DNA repair proteins including NBS1 and Mre11. The assembly of these telomere-associated PML bodies is associated with the pluripotent state of mouse ES cells, as their presence is not found in human and mouse somatic cell types. RNAi-mediated depletion of PML expression in mouse ES cells results in the disassembly of these telomere-associated PML bodies, and consequently loss of ATRX and H3.3 binding at the telomeres. These changes are accompanied by increased levels of repressive chromatin marks including H3K9me3 and H4K20me3 at the telomeres, indicating a disruption to the maintenance of the unique and less ‘heterochromatic’ histone methylation modification pattern at the telomeres in ES cells. Our study provides evidence that PML bodies play an important role in maintaining telomeric chromatin integrity. Considering the link between telomere function and chromosome stability (35), this study further reveals the function of PML bodies in regulating genome integrity (41,42), in this case, ensuring the faithful inheritance of epigenetic states at telomeres.

**MATERIALS AND METHODS**

**Cell culture**

Human HT1080 fibrosarcoma and mouse NIH3T3 transformed fibroblast were cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% FCS. Mouse ES129.1, ES-W9.5, EGRA2 and EGRA3 cells were cultured in DMEM with 15% heat-inactivated FCS and 10^3 units/ml of leukemia inhibitory factor (LIF) and 0.1 mM β-mercaptoethanol.

**Induction of cellular differentiation of mouse ES cells**

ES129.1 cells were subjected to cellular differentiation by LIF withdrawal and retinoid acid treatment. Before differentiation, >90% of cells expressed the stem-cell surface marker POU5F1 (also known as OCT4). After 3 days of differentiation, <50% expressed POU5F1. By 6 days, POU5F1 was barely detectable.

**Appending the MYC epitope to the N-terminus of H3.3A**

A standard replacement vector was used to target modified sequence to one of the endogenous alleles of the H3f3a (H3 histone, family 3A) gene. A neomycin positive selection cassette flanked by loxP sites was contained in intron 2–3, which was later removed by transient exposure to Cre recombinase. The first 15 residues of the resulting protein produced by the modified H3f3a locus were M-EQKLISEEDL-ARTK. The only other sequence change at the locus was a single loxP site contained within intron 2–3 (M.T., L.H.W. and J.R.M., unpublished data).

**Immunofluorescence and FISH analysis**

Cells were treated with microtubule-depolymerizing agent Colcemid at 37°C for 1 h and harvested for immunofluorescence analysis (43). Cells were subjected to hypotonic treatment in 0.075 M KCl, cytospin on slides and incubated in KCM buffer (120 mM KCl, 20 mM NaCl, 10 mM Tris–HCl, pH 7.2, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 0.1% (v/v) Triton X-100 and protease inhibitor). Slides were blocked in KCM buffer containing 1% bovine serum albumin (BSA), incubated with relevant primary and secondary antibodies at 37°C for 1 h. After each round of antibody incubation, slides were washed three times in KCM buffer. Slides were then fixed in KCM with 4% formaldehyde and mounted in mounting medium. Images were collected using a fluorescence microscope linked to a CCD camera system. For telomere-fluorescence *in situ* hybridization (FISH), slides were fixed in cold methanol followed by dehydration in an ethanol series before denaturation and hybridization with Cy3-conjugated telomere DNA probe (Dako).
Antibodies

Primary antibodies used include rabbit polyclonal antisera against TERF-1 (44), TERF-2 (Novus), ATRX (H300; Santa Cruz Biotechnologies); H3K9me3 (Millipore), H4K20me3 (Abcam/Millipore), DAXX (Millipore/Merck), Mre11 (Millipore/Merck); mouse monoclonal antisera against MYC tag (Millipore), POU5F1 (Santa Cruz Biotechnologies), PCNA (Proliferating Cell Nuclear Antigen; Millipore/Merck) 53BP1 (Millipore/Merck) and NBS1 (Millipore/Merck) and PML (Millipore/Merck).

Cell cycle synchronization and FACS analysis

Cells were treated with 2 mM thymidine for 12 h, released from cell cycle blockage by washing with warm medium and incubated in medium at 37°C for various time points. For fluorescence-activated cell sorting (FACS) analysis, cells were harvested, washed in 1× phosphate buffered saline (PBS), fixed with ice-cold ethanol, stained with propidium iodide and analyzed on a LSR II Becton Dickinson Flow Cytometry Analyzer.

RNAi-mediated knockdown and real-time PCR analysis

Transfections of small interfering RNA (siRNA) oligonucleotides were performed using Lipofectamine 2000 (Invitrogen). These oligonucleotides have been pre-validated to confirm their targeting specificity to messenger RNAs of PML, NBS1 and Mre11. A set of control scrambled siRNA oligonucleotides was also used. Cells were harvested 24–48 h after RNAi-mediated knockdown for the assessment of the levels of endogenous protein expression by real-time polymerase chain reaction (PCR) analysis using the SYBR system (Applied Biosystem). As internal controls, specific primers corresponding to house-keeping gene Actin were used in real-time PCR changes in expression levels were calculated according to the manufacturer’s instruction.

CO-FISH

Cells were incubated for 16–20 h in fresh medium containing BrdU (10 μg/ml). An hour before harvesting, Colcemid was added to the media to accumulate mitotic cells. Cells were harvested and resuspended in 0.075 M KCl (pre-warmed to 37°C). Ice-cold methanol-acetic acid (3:1 ratio) was added to cell suspension. The cell suspension was spun (5 min at 1000 rpm) and washed twice in methanol-acetic acid. Cells were dropped onto slides and allowed to dry overnight. Slides were rehydrated in 1× PBS for 5 min at room temperature, incubated with 0.5 μg/ml RNase A (in PBS, DNase free) for 10 min at 37°C and stained with 0.5 μg/ml Hoechst 33258 in 2× SSC for 15 min at room temperature. Subsequently, slides were placed in a shallow plastic tray, covered with 2× SSC and exposed to 365 nm ultraviolet light at room temperature for 45 min. The BrdU-substituted DNA strands were digested with at least 10 U/μl of Exonuclease III at room temperature for 30 min. Slides were washed in 1× in PBS, dehydrated in ethanol series 70%, 95%, 100% and air dried. FISH was performed as described above, except that slides were not subjected to DNA denaturation.

Chromatin immunoprecipitation assays (CHIP)

Cells were fixed in 0.8% paraformaldehyde in 1× PBS, washed extensively in 1× PBS, lysed in ice-cold Lysis buffer [1% sodium dodecyl sulphate (SDS), 10 mM EDTA, 50 mM Tris–HCl, pH 8.0, and protease inhibitors; sonicated chromatin products of ~100–300 bp] and diluted 10× in Dilution buffer (20 mM Tris–HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, protease inhibitors and 1 mg/ml BSA). ChIP was performed with the relevant antibody and captured with Protein-A/G Sepharose. DNA-protein complex was washed with 1× Wash buffer I (20 mM Tris–HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 1% Triton X-100 and 2 mM EDTA), 2× Wash buffer II (20 mM Tris–HCl, pH 8.0, 250 mM NaCl, 0.1% SDS, 1% Triton X-100 and 2 mM EDTA) and eluted in 1× SDS and 100 mM NaHCO3. Eluate fraction was de-crosslinked by high-salt treatment (200 mM NaCl) at 60°C followed by proteinase K treatment at 50°C. DNA extracted was subjected to dot blot analysis.

Dot blot analysis

Fifty nanograms of DNA was diluted with 0.6 M NaCl, denatured (by heating DNA at 100°C for 5 min and cooled on ice for 5 min), transferred onto Hybond N+ nitrocellulose membrane and rinsed in 0.5 M NH4SO4. The membrane was incubated in 0.4 N NaOH at RT for 5 min, followed by neutralization with 2× SSC twice. In subsequent, the membrane was subjected to Southern blot analysis with either γ-32p ATP-end-labeled (TTAGGG)4 telomere probe. Signal intensities were analyzed with Typhoon PhosphoImager System and ImageQuant software.

Sequences of siRNA oligonucleotides

PML set 1 GCAGUGGCAGAGGAGCUUUU GACUCACAGUGGCATGAGGAACUAGG CAC
PML set 2 GCUGCAGUCCAGAGGAAAUUU CAGCGGACUACCAGGAAUAGCUUGGC CAG
PML set 3 CCUCAAGAUUGACAAGAUAAUU CUUUUGACCUCUAAUGCAAGAACCC CA
PML set 4 CGUGUAAAAGGGGAAAAACAAAAUU UUGCUUUUCCCCGGUUAAGCCCGG CACG
MreII set 1 GAGGCUUUGAACCCUUUCAAAUU UUGAACGGUCUAAAGCUCUCUUU MreII set 2 GGGCACAACACUACAGAUAUU UUGCUAGUGUGUGUCCCUUCU NBS1 set 1 GCCCUUGGGUUUGUUUGGCUUUU AGAACCAACACAAAGGGCCUU NBS1 set 2 CCAGAAACUAAGUGUAUU AUUUACACAUAGAUUUCUGGUUU
we determined the assembly of telomere-associated PML bodies in mouse ES129.1 cells subjected to cellular differentiation. Before induction of cellular differentiation by LIF withdrawal and retinoid acid treatment (12,13), >90% of cells expressed the stem-cell surface marker POU5F1 (data not shown). After 3 days, only ~50% expressed POU5F1, and it was barely detectable after 6 days. The presence of telomere-associated PML bodies remained relatively prominent in the first 3 days of differentiation (Table 1), with 91.43% of cells showing ≥5 positive ATRX/telomeres co-staining foci at PML bodies per cell. However, after 6 days, this positive staining pattern started to decrease and was reduced to only 14.29–28.57% after 9–12 days (Figure 2C and Table 1). This loss in telomere-associated PML bodies was not simply a consequence of a change in cellular growth rate, as these cells were still actively dividing after differentiation. These observations indicate that the assembly of telomere-associated PML body is linked to a differentiation-state–specific process.

Considering the role of ATRX and DAXX as chaperones that load H3.3 into chromatin (21), we propose to study the function of these telomere-associated PML bodies as a platform that facilitated the recruitment of ATRX/DAXX complex and the nucleosomal deposition of H3.3 at the telomeres. There is evidence that the number of PML bodies is increased during DNA replication at S phase (48). Moreover, the co-localization of ATRX and H3.3 with the telomeres in mouse ES cells is most prominent during S phase (12,13). To determine if the assembly of the telomere-associated PML bodies is coupled to cell cycle progression, we performed immunofluorescence analysis on ES129.1 cells synchronized using a thymidine G1/S block protocol. The cell cycle progression of cells was assessed by FACS analysis (12,13). Following the release, ES129.1 cells progressed through S phase at 4–6 h after release, entered M phase at 8 h, and re-entered G1 phase at 10 h. The localization of ATRX/telomeres at the PML bodies occurred predominantly at S phase, with 88.57–91.43% of cells showing ≥5 positive co-staining foci of ATRX/telomeres at PML bodies per cell after 4–6 h of release (Table 2). This suggests that the assembly of telomere-associated PML bodies in mouse ES cells is in synchrony with S phase of cell cycle (49). These PML bodies may be required for the establishment of chromatin marks at newly replicated telomeric DNA to ensure a proper maintenance of telomeric chromatin integrity.

DNA repair proteins are not required for assembly of telomere-associated PML bodies

To define the function of PML bodies in maintaining telomeric chromatin integrity, we determined the presence of other proteins at telomere-associated PML bodies. Beside ATRX and DAXX, we detected the presence of DNA repair and recombination proteins NBS1 and Mre11 at the PML bodies and at the telomeres (examples are shown in Figure 3). The co-localization of NBS1 and Mre11 with telomeres at the PML bodies was confirmed...
by telomere FISH analysis. In human ALT cancer cells, the presence of these DNA repair proteins is vital for APB assembly (37,38). Depletion of the MRN (Mre11/Rad50/NBS1) complex results in the disassembly of APBs and maintenance of telomeric recombination or ALT activity. To determine the requirement of NBS1 and Mre11 in maintaining the assembly of telomere-associated PML bodies in ES cells, we performed RNAi-mediated knockdown of NBS1 and Mre11 expression (Supplementary Table S1a and Figure S1). The FACS analysis showed that transient loss of expression of these proteins did not cause a severe cell cycle block (Supplementary Table S1b). Unlike that of the ALT cancer cells (37,38), loss of function of NBS1 and Mre11 following knockdown had no significant impact on the assembly of telomere-associated PML bodies (Supplementary Table S1c), indicating that they are not required for the assembly of telomere-associated PML bodies in mouse ES cells.

Loss of PML bodies induces a telomeric dysfunction phenotype

PML is the most prominent component of PML bodies, and its presence is required for their assembly. To determine the role of PML bodies in maintaining telomeric chromatin integrity, we established RNAi-mediated knockdown of PML expression in mouse ES129.1 cells. As shown by real-time reverse transcription PCR assay, two of these oligonucleotide sets (set 3 and 4) resulted in 70–80% depletion of PML expression (Supplementary Table S2a). The reduction in PML protein levels was shown by western blot and immunofluorescence analyses in Figure 4A and B. And importantly, the loss of PML expression reduced the assembly of telomere-associated PML bodies. The reduced expression of PML did not significantly impact the cell cycle progression as shown by FACS analysis (Supplementary Table S2b) and positive immunostaining with an antibody against proliferating cell nuclear antigen (PCNA is a cofactor for DNA replication and is expressed in S phase) (Supplementary Figure S2 and Table S2c).

We have previously shown that RNAi-mediated knockdown of H3.3 and ATRX in mouse ES cells induced telomere-dysfunction phenotypes (12,13). This was indicated by an increase in the number of cells with telomere-induced dysfunctional foci (TIF; a marker for DNA damage at the telomeres) (50). Here, we also assessed the effects of the loss of PML bodies on telomere structural integrity by staining with an antibody against a DNA damage marker 53BP1 (Figure 4C and D). In ES129.1 cells transfected with control scramble siRNA oligonucleotides, only 10–14% of cells showed 5 TIFs per cell. In contrast, cells subjected to PML-specific RNAi knockdown showed a >4-fold (increased from 10–14% to 38–46%) increase in the population of cells showing 5 TIFs per cell (Figure 4C and D and Supplementary Table S3a), demonstrating that telomere functional integrity was impaired following the loss of telomere-associated PML bodies in mouse ES cells.

Loss of PML bodies impacts on establishment of epigenetic marks at telomeres

Considering the link of PML bodies to telomeric recombination in ALT cells (36–40), we performed chromosome orientation (CO)-FISH assay (Supplementary Figure S3) to determine if loss of PML bodies affected the rate of sister chromatid exchange at telomeres (TSCE). In CO-FISH assays, the CO-FISH hybridization normally displays only single telomere-FISH hybridization signal per two sister chromatids. If TSCE occurs, the signal is split and appears on both sister chromatids. No increase in TSCE was observed in ES129.1 subjected to either scramble control or PML-specific RNAi knockdown (Supplementary Table S3b), suggesting that telomere-associated PML bodies in mouse ES cells were not
Figure 2. ATRX co-localized with telomeres at PML bodies in mouse ES cells. (A and B) ES129.1 and W9.5 cells showed clear co-staining of ATRX (A-B ii) with telomere FISH signals (A–B iii) at the PML bodies (A and B iv). (C) The co-staining pattern of ATRX (ii) with telomeres (iii) at the PML bodies (iv) started to decrease after 6 days of differentiation. Part ‘i’ is the merged figures and ‘ii, iii and iv’ the split images of ‘i’. The arrows show some ‘examples’ of co-localized foci of ATRX/telomeres at PML bodies. (Scale bars: 5 μm).

Table 1. Localization of telomere at PML bodies during ES cell differentiation

<table>
<thead>
<tr>
<th>Time period of differentiation (days)</th>
<th>0</th>
<th>3</th>
<th>6</th>
<th>9</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cells with ≥5 positive foci of telomere-associated PML bodies (total of 35 cells scored)</td>
<td>32</td>
<td>34</td>
<td>27</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Percentage of cell population with ≥5 positive foci of telomere-associated PML bodies (%)</td>
<td>91.43</td>
<td>97.14</td>
<td>77.14</td>
<td>28.57</td>
<td>14.29</td>
</tr>
</tbody>
</table>

Immuno-fluorescence analysis was performed on ES129.1 cells following induction of cellular differentiation (Figure 2). For each time-point, 35 cells were assessed for co-staining pattern of telomere FISH and anti-PML antibody staining. Numbers of cells with ≥5 co-staining signals per cell were shown. In the initial 3 days, >97% of the cell population showed ≥5 positive signals per cell. After 6 days of induction of differentiation, the percentage of cells with ≥5 positive signals per cell was reduced to 77% and this was further reduced after 9–12 days of differentiation.

Table 2. Cell cycle analysis of telomeric localisation at PML bodies

<table>
<thead>
<tr>
<th>Time period after G1/S release (hours)</th>
<th>0</th>
<th>2</th>
<th>4</th>
<th>6</th>
<th>8</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cells with &lt;5 positive foci of telomere-associated PML bodies (total of 35 cells scored)</td>
<td>28</td>
<td>13</td>
<td>4</td>
<td>3</td>
<td>22</td>
<td>27</td>
</tr>
<tr>
<td>Percentage of cell population with &lt;5 positive foci of telomere-associated PML bodies (%)</td>
<td>80.00</td>
<td>37.14</td>
<td>11.43</td>
<td>8.57</td>
<td>62.86</td>
<td>77.14</td>
</tr>
<tr>
<td>Number of cells with ≥5 positive foci of telomere-associated PML bodies (total of 35 cells scored)</td>
<td>7</td>
<td>22</td>
<td>31</td>
<td>32</td>
<td>13</td>
<td>8</td>
</tr>
<tr>
<td>Percentage of cell population with ≥5 positive foci of telomere-associated PML bodies (%)</td>
<td>20.00</td>
<td>62.86</td>
<td>88.57</td>
<td>91.43</td>
<td>37.14</td>
<td>22.86</td>
</tr>
</tbody>
</table>

Combined immuno-fluorescence/telomere FISH analysis was performed on ES129.1 cells released from thymidine-induced G1/S block. Cells progressed through S phase at 4–6h after release, entered mitosis at 8h and re-entered G1 phase at 10h. For each time-point, 35 cells were quantified for co-staining signals of ATRX and telomeres at the PML bodies. Numbers of cells with ≥5 co-staining signals per cell were shown. At 0–2h after release, only a low percentage of cell population showed ≥5 co-staining signals per cell. After 4–6h of release, there was a significant increase in cell population (88.57–91.43%) showing ≥5 positive signals, suggesting that the association of telomeres with PML bodies occurred predominantly during S phase. At mitosis (8h after release; during which PML bodies de-assemble), telomeres de-localized from PML bodies and the cell population showing ≥5 positive signals decreased to basal level.
Figure 4. Effects of loss of PML bodies on telomere function. (A) ES129.1 cells were depleted of PML expression with two sets of siRNA oligonucleotides (set 3 and 4; Supplementary Table S2), followed by western blot analysis with antiserum against PML (i, short exposure; ii, long exposure of blot—the blot was overexposed to detect all PML isoforms) and β-tubulin (iii). Equal loading of protein was achieved by normalization against β-tubulin level. (iv) ‘Low bars’ were graphed according to protein bands in (i), whereas ‘High bars’ according to protein bands in (ii). In PML depleted cells, PML levels (lanes 2 and 3) were reduced by \( \% \) 90% 48 h after transfection compared with cells transfected with control siRNA oligonucleotides (lane 1). (B) Two sets of siRNA oligonucleotides (set 3 and 4) were used to deplete PML expression in ES129.1 cells. Immunofluorescence analysis was performed using antiserum against PML. Examples of ES129.1 cells showing the loss of PML bodies are shown by arrowheads. (C) TIFs were detected by co-staining of telomeres (TERF-1 staining; iii) with 53BP1 signals (iii) (see Supplementary Table S3a for scoring data). In ES129.1 cells transfected with control scramble siRNA oligonucleotides, < 5 TIFs were detected (i), whereas 48 h of RNAi-mediated knockdown of PML induced the formation of TIFs (11 TIFs in II and 15 TIFs in III, respectively). Arrowheads show examples of TIFs. (D) Data were sub-grouped according to number of TIFs (< 5, 5–9, 10–14 and > 14) per cell. A normal cell contains \( \% \) 2–3 TIFs on average, so a threshold of > 4 TIFs was used. When depleted of PML expression, percentage of cells with \( \% \) 5 TIFs (85 cells were counted) rose by 3–5-folds (from 10–14% to 38–46%).

Figure 3. Proteins that localized at telomeres-associated PML bodies. (A–C) DNA repair protein MRE11 (Aii) was present at PML bodies (Aiii) in ES129.1 cells. NBS1 (B–C iii) was also present at PML bodies (Bii) and telomeres (Cii; TERF-1 staining). (D) NBS1 (iv) co-localized with ATRX (ii) at telomeres (iii) in ES129.1 cells. Part ‘i’ is the merged figures and ‘ii, iii and iv’ the split images of ‘i’. The arrows show some ‘examples’ of co-localized foci. (Scale bars: 5 μm).
directly involved in telomeric recombination. Our proposal is consistent with a recent work showing that the association of induced ‘long telomeres’ with PML bodies in telomerase overexpressing cells is not accompanied with an increase in TSCE (51), highlighting a distinct role of PML bodies in telomere maintenance. In consideration of the induction of telomeric damage in PML-depleted cells (Figure 4C and D), we propose that PML bodies is involved in maintaining a functional epigenetic state such as the recruitment of ATRX and H3.3 at the telomeres in mouse ES cells (12,13).

To test this hypothesis, we determined the impact of the loss of PML bodies on the maintenance of epigenetic marks at telomeres. Interestingly, depletion of PML expression and consequential loss of PML bodies led to a reduction in the presence of ATRX at the telomeres (Figure 5A–C). To confirm this, we had specifically assessed co-localization of ATRX and telomeres at PML bodies in PML knockdown cell population during S phase; these cells were blocked at G1/S by thymidine treatment, followed by release into S phase for immunofluorescence analysis. In PML-depleted cells, we found a significant drop in percentage of cell population showing five or more telomere-associated PML bodies, and this loss of assembly of telomere-associated PML bodies resulted in a reduction in the level of H3.3ser31P signals at the telomeres during S phase (percentage of cells showing ≥5 positive foci per cell reduced from 82.6 to 42.9%; Table 3).

Considering the role of ATRX as chaperone for assembly of H3.3 nucleosomes at the telomeres in mouse ES cells, we also determined if loss of PML bodies also affected H3.3 level at the telomeres. To determine this, we assessed the level of H3.3 phosphorylated at serine 31 (H3.3ser31P) as we have previously shown that telomeres in ES cells are enriched with H3.3ser31P during mitosis (13). Indeed, the reduced association of ATRX at telomeres was also accompanied by a decrease in H3.3ser31P level at the telomeres (Figure 5D and E). Specifically, loss of PML bodies led to a 42% reduction in the level of H3.3ser31P at the telomeres during mitosis (Table 4). These data suggest that PML bodies are required for maintaining ATRX/H3.3 levels at the telomeres.

Table 3. Assembly of telomere-associated PML bodies in PML knockdown cells

<table>
<thead>
<tr>
<th>Number of co-localized foci (% of cells)</th>
<th>Control RNAi / PML RNAi</th>
<th>Control RNAi / PML RNAi</th>
<th>Control RNAi / PML RNAi</th>
<th>Control RNAi / PML RNAi</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;4</td>
<td>17.14/57.14</td>
<td>14.29/60</td>
<td>20/54.29</td>
<td>54.29</td>
</tr>
<tr>
<td>5–9</td>
<td>54.29/25.71</td>
<td>60/25.71</td>
<td>54.3/31.43</td>
<td>31.43</td>
</tr>
<tr>
<td>10–14</td>
<td>17.14/4.257</td>
<td>20/5.71</td>
<td>17.1/8.57</td>
<td>8.57</td>
</tr>
<tr>
<td>&gt;14</td>
<td>11.43/2.857</td>
<td>5.71/2.86</td>
<td>5.71/8.57</td>
<td>5.71</td>
</tr>
<tr>
<td>% of cell with ≥5 positive foci</td>
<td>82.86/42.86</td>
<td>85.71/40</td>
<td>40/80</td>
<td>45.71</td>
</tr>
<tr>
<td>Average % of cells</td>
<td>Control RNAi = 82.6%</td>
<td>PML RNAi = 42.9%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RNAi-mediated knockdown was performed on ES129.1 cells with specific PML siRNA oligonucleotides (set 3) and a set of scramble control siRNA oligonucleotides for 48 h. Cells were blocked at G1/S by thymidine treatment, then released into S phase (released for 4h to enrich for S phase cells; confirmed by FACS analysis). These cells were harvested for immunofluorescence. RNAi knockdown of PML and loss of assembly of PML bodies led to a significant drop in S phase cell population showing ≥5 positive co-staining signals per cell of ATRX antibody staining and telomere FISH (reduced from 82.6% to 42.9%; see Figure 5).

Table 4. H3.3ser31P intensities at telomeres in PML knockdown cells

<table>
<thead>
<tr>
<th>Experiments</th>
<th>Samples</th>
<th>Centromere signals</th>
<th>H3.3ser31P signals</th>
<th>Ratio of H3.3ser31P/centromere</th>
<th>Fold of change in ratio of H3.3ser31P/centromere</th>
</tr>
</thead>
<tbody>
<tr>
<td>N = 1</td>
<td>Control RNAi</td>
<td>560</td>
<td>471</td>
<td>0.84</td>
<td>0.61</td>
</tr>
<tr>
<td></td>
<td>PML RNAi</td>
<td>688</td>
<td>354</td>
<td>0.52</td>
<td></td>
</tr>
<tr>
<td>N = 2</td>
<td>Control RNAi</td>
<td>558</td>
<td>386</td>
<td>0.69</td>
<td>0.49</td>
</tr>
<tr>
<td></td>
<td>PML RNAi</td>
<td>766</td>
<td>259</td>
<td>0.34</td>
<td></td>
</tr>
<tr>
<td>N = 3</td>
<td>Control RNAi</td>
<td>359</td>
<td>333</td>
<td>0.93</td>
<td>0.63</td>
</tr>
<tr>
<td></td>
<td>PML RNAi</td>
<td>386</td>
<td>225</td>
<td>0.58</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Average fold of change in ratio of H3.3ser31P/centromere signals</td>
<td>0.58 (reduced by 42%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ES129.1 cells were transfected with either scramble control or PML-specific siRNA oligonucleotides (set 3). Immunofluorescence analysis was performed using the human CREST antibody that recognized centromere proteins (including CENP-A, CENP-B and CENP-C) and H3.3ser31P (see Figure 5). Depletion of PML expression and loss of assembly of PML bodies resulted in a reduced level of H3.3ser31P signals at the telomeres in mitotic cells (signal intensities reduced by 42.9%).
depleted of PML bodies. These differences in histone methylation profile were unlikely caused by changes in expression of histone modifiers or telomere proteins as shown by western blot analysis (Figure 6). Instead, we propose that these data support our proposal of the importance of PML bodies in ensuring the maintenance of specific epigenetic states at telomeres in mouse ES cells.

**DISCUSSION**

In this study, we examined the platform on which telomeric chromatin state is established, in particular, the assembly of H3.3 nucleosomes by ATRX and DAXX at the telomeres (12,21–23) in mouse ES cells. Our data show that PML bodies act as sites for H3.3 deposition by ATRX and are important for the faithful maintenance of epigenetic information at telomeres in ES cells.

Although PML bodies have been regarded primarily as sites of storage where proteins accumulate and undergo post-translational modifications (35), there are studies showing interaction of specific genomic sites such as the histocompatibility (MHC) class I gene cluster (52) and CMV promoter array (45) with PML bodies. Here, we show that telomeres are associated with PML bodies in mouse ES cells, providing evidence for the propensity for

---

**Figure 5.** Effects of loss of PML bodies on binding of ATRX and H3.3 at telomeres. ES129.1 cells transfected with control scramble siRNA oligonucleotides are indicated as ‘control’, whereas cells subjected to knockdown with PML-specific siRNA oligonucleotides are indicated as ‘PML RNAi’. (A) RNAi knockdown of PML in ES129.1 cells resulted in a loss in the formation of PML bodies (iii; cell on the left), leading to de-localization of ATRX (ii; arrows). (B and C) De-localization of ATRX from telomeres was confirmed by telomere FISH analysis. Compared with scramble control ES129.1 cells (B; control), RNAi knockdown of PML (C; PML RNAi) led to disassembly of PML bodies (Civ), resulting in ATRX de-localization (Cii) from the telomeres (Ciii; telomere FISH) (see Table 3). (D and E) RNAi knockdown of PML and loss of PML bodies (E; PML RNAi) also resulted in a reduction in the co-localization of myc-H3.3 (iii) with ATRX (ii) in ES129.1 cells. (F and G) In addition, depletion of PML expression and loss of PML bodies (G; PML RNAi) also resulted in a reduction in the level of H3.3ser31P at the telomeres on metaphase chromosomes (examples of positive H3.3ser31P staining at telomeres are indicated by arrows, whereas examples of the absence of H3.3ser31P signal at telomeres are indicated by arrowheads; see Table 4 for quantification) (Scale bars: 5 μm).
PML bodies to associate with specific genomic loci. The assembly of these telomere-associated PML is linked to the pluripotent state of cells, as these bodies are not found in somatic cells and are reduced in number in differentiated ES cells. It is currently unknown what factor(s) may direct the localization of telomeres to the PML bodies in ES cells. It is, however, tempting to speculate that the unique epigenetic code surrounding the telomeres may direct the formation of PML bodies. Indeed, the hypomethylation status of telomeric DNA in human ALT cancers (53) and mouse DNMT-null cells (10) and the loss of H4K20me3 at telomeres in Suvar-4-20-h knockout cells (11) may promote the assembly of PML bodies surrounding the telomeres in these cells, thus, supporting this possibility. In the same light, the ‘less heterochromatic’ nature of the ES cell telomeric chromatin with lower levels of H3K9me3 and H4K20me3 (13) may drive association of telomeres with PML bodies.

In mouse ES cells, loss of PML bodies following RNAi knockdown of PML induces telomere dysfunctional phenotype and affects binding of ATRX and H3.3 at telomeres. Considering the role of ATRX/DAXX (46) in directing the H3.3 nucleosomal assembly (21,22), the increased telomere dysfunction phenotype in PML-depleted ES cells could be brought about by the disruption in the complex formation between ATRX and DAXX, and a failure in H3.3 deposition at the telomeres.

The depletion of PML expression in mouse ES cells also results in a change in telomeric chromatin properties—as demonstrated by an increase in the level of repressive histone marks including H3K9me3 and H4K20me3 at telomeres. These underlying changes in histone marks indicate a possible disruption to the maintenance of a unique and ‘less heterochromatic’ chromatin state at telomeres in the absence of telomere-associated PML bodies. It is reasonable to suggest that these changes in patterns of histone methylation may contribute instrumentally to the increased telomere dysfunctional phenotype at telomeres in mouse ES cells.

Previous studies in immunodeficiency, centromeric instability and facial dysmorphism (ICF) syndrome (54), a pathological condition caused by mutations in the DNA methyltransferase DNMT3B gene, have provided important clues into how association of PML bodies could contribute to epigenetic modifications. In ICF patient cells, Bloom syndrome protein (BLM) and Topo IIIα within PML bodies resolve the aberrant recombination DNA products formed during replication due to hypomethylation of 1qh and 16qh pericentric satellite DNA, while DAXX, BRCA1 and HP-1 re-establish a repressive and compacted state at these repeats (55). Although it is unclear how changes of epigenetic state at 1qh and 16qh pericentric satellite DNA have promoted the assembly of PML bodies around these loci, these studies clearly demonstrate the involvement of PML bodies as sites for chromatin state re-establishment following DNA replication. In light of this, we propose that PML bodies serve as a fitting platform for recruitment and/or stabilization of chromatin remodeling proteins at telomeres following DNA replication (49). Within the PML bodies, DNA damage processing machinery (e.g. Mre11 and NBS1) could promote telomere replication (49), while ATRX and H3.3 take part in chromatin remodeling by recruiting other chromatin factors such as HP-1 (12). Additionally, the sequestration of telomeric complex within the PML bodies could ensure the assembly of a less ‘heterochromatic’ telomeric chromatin state with lower levels of H3K9me3 and H4K20me3 (13,14) and prevent an aberrant assembly of chromatin marks at telomeres that are not compatible with the pluripotent state of ES cells. This may also explain the presence of high levels of H3K9me3 and H4K20me3 at telomeres in the absence of PML bodies in PML knockdown cells.

It is interesting that the loss of PML bodies also resulted in an increase in TERF-1 level at the telomeres in mouse ES cells. Previous studies have shown that loss of function
of ATRX and DAXX induces level of telomeric TERRA transcription (23) and that TERRA RNA binding activity could directly affect association of Shelterin complex and H3K9 methylation at telomeres (56). Considering ATRX/ H3.3 recruitment at telomeres is affected in the absence of PML bodies, future studies will be necessary to determine if TERRA transcription is up-regulated in PML knockdown ES cells and if an increase in TERRA transcript level has a part in promoting increased association of TERFI, H3K9 me3 and H4K20me3 at the telomeres in these cells.

Our study builds on the known function of PML bodies as a passive storage domain for proteins or as a reservoir for post-translational modifications; these nuclear bodies bring telomeres into an environment enriched with the appropriate epigenetic modifiers in ES cells. We provide evidence for the important function of PML bodies as active epigenetic regulators in ensuring that epigenetic information on telomeres is properly established and securely inherited on telomere repeats. Our study also provides an important insight into function of PML bodies in the maintenance of genome stability.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online: Supplementary Tables 1–4 and Supplementary Figures 1–3.

FUNDING
National Health and Medical Research Council (NHMRC) of Australia and Victorian Government’s Operational Infrastructure Support Programme. L.H.W. receives a Career Development Award from NHMRC. Funding for open access charge: NHMRC Australia.

Conflict of interest statement. None declared.

REFERENCES


